Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

(2009) M. Tonelli et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia

(2009) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

Erythropoietin in Cancer Patients

(2008) John A. Glaspy   Annual Review of Medicine

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2008) Robert E. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

(2008) Laurent Bastit et al.   JOURNAL OF CLINICAL ONCOLOGY